INTERNATIONAL JOURNAL OF ONCOLOGY 29: 903-910, 2006
903
OY-TES-1 expression and serum immunoreactivity
in epithelial ovarian cancer
JONATHAN TAMMELA1, AKIKO UENAKA5, TOSHIRO ONO6, YUJI NOGUCHI5, ACHIM A. JUNGBLUTH7,
PAULETTE MHAWECH-FAUCEGLIA4, FENG QIAN1,2, SALLY SCHNEIDER2, SAMEER SHARMA1,
DEBORAH DRISCOLL3, SHASHIKANT LELE1, LLOYD J. OLD7, EIICHI NAKAYAMA5 and KUNLE ODUNSI1,2
Departments of 1Gynecologic Oncology, 2Immunology, 3Biostatistics, and 4Pathology, Roswell Park Cancer Institute Buffalo,
NY, USA; 5Department of Immunology, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan;
6Department of Radiation Research, Okayama University Advanced Science Research Center; 7Ludwig Institute
for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Received March 30, 2006; Accepted May 19, 2006
Abstract. OY-TES-1 is a novel target that belongs to the family
of ‘cancer/testis’ (CT) antigens. Our goal was to examine the
expression and immunogenicity of OY-TES-1 in epithelial
ovarian cancer (EOC) to determine its potential as a target
for vaccine therapy. OY-TES-1 expression was determined
by one-step reverse transcriptase PCR on 100 EOC samples,
5 EOC cell lines, and a panel of normal tissues. Immunohistochemistry (IHC) was performed on the same panel of
EOC tissues. Sera from a sub-group of patients were tested
for OY-TES-1 antibody by ELISA. Thymus and leukocytes
were weakly positive for OY-TES-1 while the remaining 5
normal tissues were negative. Expression of OY-TES-1 by
either RT-PCR and/or IHC was demonstrable in 69/100 (69%)
tumors. Humoral immunity to OY-TES-1 was demonstrated
in 1/10 (10%) serum samples from patients whose tumors
expressed the antigen. The median follow-up of the patient
population was 34 months. There was no correlation between
antigen expression and stage, grade, histology and survival.
OY-TES-1 is expressed in 69% of patients with EOC, is absent
from normal ovarian tissue, and a proportion of patients show
evidence of a specific humoral immune response. These
findings make OY-TES-1 an attractive target for antigen-specific
immunotherapy in EOC.
Introduction
Ovarian cancer is the leading cause of death in women
with gynecologic malignancies (1). The majority of patients
are diagnosed at an advanced stage, and despite modest
_________________________________________
Correspondence to: Dr Kunle Odunsi, Divisions of Gynecologic
Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
E-mail: kunle.odunsi@roswellpark.org
Key words: ovarian tumor antigen, immunogenicity, immunohistochemistry, antibody, prognostic indicator
improvements in survival with the use of adjuvant chemotherapy with platinum/paclitaxel based chemotherapy, overall
survival for patients with advanced epithelial ovarian cancer
(EOC) remains poor (2). A potential strategy for improving
outcome in patients with EOC is to minimize recurrence
by utilizing the immunotherapy approach in those that
show complete response to front-line therapy. These patients
can be presumed to have micrometastatic disease that can
potentially be recognized by the immune system and lead to
an improvement in remission rates. This approach requires the
identification and characterization of tumor antigens with high
frequency expression in tumor tissues, restricted expression in
normal tissues, and inherent immunogenicity. As a consequence
of advances in approaches for analyzing immune reactivity to
cancer in the context of the autologous host, a number of
human tumor antigens have been identified. These antigens
are categorized into various classes such as differentiation
antigens [e.g. tyrosinase (3)], mutational antigens [e.g. P53
(4)], amplified antigens [e.g. Her2/neu (5)], splice variant
antigens [e.g. NY-CO-37/PDZ-45 (4)], viral antigens [e.g.
HPV (6)], and cancer-testis (CT) antigens [e.g. MAGE (7),
NY-ESO-1 (8) and OY-TES-1 (9)].
The ‘cancer-testis’ (CT) antigens are a unique class of
antigens that demonstrate high levels of expression in adult
male germ cells, but generally not in other normal adult
tissues, and aberrant expression in a variable proportion of
a wide range of different cancer types (10-12). This fact
makes CT antigens especially attractive targets for specific
immunotherapy. The expression of a number of CT antigens
has been investigated in EOC. NY-ESO-1 is expressed in ~40%
(13), MAGE-A1 in ~20% (14), MAGE-A3 in ~20% (14),
MAGE-A4 in ~57% (15), and SCP-1 in 15% (16). OY-TES-1
was identified as an additional member of the cancer/testis
family of antigens (9). OY-TES-1 is the human homologue of
proacrosin binding protein sp32 precursor originally identified
in mouse, guinea pig, and pig (17), and maps to human chromosome 12p12-p13.
The aim of the present study was to determine the frequency
of expression of OY-TES-1 mRNA and protein in epithelial
ovarian cancer. We also examined the spontaneous antibody
904
TAMMELA et al: OY-TES-1 EXPRESSION AND IMMUNOGENICITY IN OVARIAN CANCER
response against OY-TES-1 in a subset of EOC patients. A
secondary objective was to examine the relationship between
OY-TES-1 expression and clinical outcome. Our results
showed a high frequency of OY-TES-1 expression in EOC,
and would suggest that OY-TES-1 is a promising candidate
for specific immunotherapy in epithelial ovarian cancer.
Materials and methods
Patients and specimens. Formalin-fixed paraffin-embedded
and flash frozen tissue specimens were obtained from patients
undergoing debulking surgery for epithelial ovarian cancer at
the Roswell Park Cancer Institute, Buffalo, NY between
1995 and 2003. All tissue specimens were collected under an
approved protocol from the Institutional Review Board (IRB).
All pathology specimens were reviewed in our institution and
tumors were classified according to WHO criteria (18). In a
subset of patients, serum samples were also available over
extended periods of time during the course of disease. The
medical records of the patients were also retrospectively
reviewed under an approved IRB protocol. The review included
outpatient and inpatient treatment, including surgery and
chemotherapy. Study outcomes included overall survival and
time to progression, each measured from the time of definitive
surgery. Progression was defined as objective evidence of
recurrence, since all therapy was given in the adjuvant setting.
The duration of overall survival was the interval between
diagnosis and death. Observation time was the interval
between diagnosis and last contact (death or last follow-up).
Data were censored at the last follow-up for patients with no
evidence of recurrence or progression.
Cell lines. Five ovarian cancer cell lines were purchased
from the American Type Culture Collection and grown in the
recommended media under standard conditions. These were
SVOV3, OVCA-429, OVCA-432, SK-OV-3, and OVCAR-3.
The immortalized human normal ovarian surface epithelial
cell lines, IOSE and HOSE were grown in the recommended
media under standard conditions. These were gifts from Dr
Nancy Auersperg (University of British Columbia, Vancouver,
BC), and Dr Sam Mok (Harvard University, Boston, MA)
respectively. Normal human tissue RNAs were obtained from
Clontech (Palo Alto, CA) or isolated from the tissues obtained
from the Tissue Procurement Facility of the Roswell Park
Cancer Institute. The normal tissue RNAs from Clontech are
from a mixture of tissues from a number of individuals who
died of trauma.
Total tissue RNA isolation. Total tissue RNA was isolated
from frozen tumor tissues and from ovarian cancer cell lines,
using the TRIReagent (Molecular Research Center Inc.,
Cincinnati, OH) according to the manufacturer's protocol.
Potentially contaminating DNA was removed by treating with
RNase-free DNase I (Boehringer-Mannheim, Mannheim,
Germany). After phenol treatment and drying, RNA was
dissolved in RNase-free H2O. The resulting RNA concentration
was measured spectrophotometrically (GeneQuant; Amersham
Pharmacia Biotech Ltd., Cambridge, UK), and the quality of
the RNAs was checked by electrophoresis on 1% agarose
gel.
RT-PCR analysis of OY-TES-1 expression. Two micrograms
of each RNA sample were subjected to cDNA synthesis
using the Ready-To-Go first strand synthesis kit (Pharmacia,
Uppsala, Sweden). PCR was subsequently performed to
analyze expression of OY-TES-1. A 604-bp long OY-TES-1
specific PCR product was amplified using OY-TES-1 specific
sense 5'-AAGGACAGGGGACTAAGGAG-3' and antisense
5'-CCGTACAAATCCAGCCCGTA-3' primers (9). Glyceraldehyde-3-phosphodehydrogenase (GAPDH) specific sense
5'-GCTTCCCGTTCCTCAATTTTGAAG-3' and antisense
5'-ATGGGAAGGTGAAGG-TCGGAG-3' primers were
used to obtain a 195-bp PCR product as a control. PCR was
performed in a PTC-100 (Programmable Thermal Controller,
MJ Research, Inc.) and included 60-min incubation at 50˚C
for reverse transcription and 15 min for enzyme inactivation
at 95˚C, followed by 30 cycles of PCR. Each PCR cycle
consists of a 1-min denaturation at 94˚C followed by a 30-sec
annealing at 62˚C and 1-min and 30-sec extension at 72˚C.
After the last cycle, the final extension step was at 72˚C
for 10 min. The PCR products were visualized by ethidium
bromide staining after separation over a 1.5% agarose gel.
Recombinant OY-TES-1 protein. OY-TES-1 was expressed
in Escherichia coli by using the histidine-tag-containing
vector pQE30 (Qiagen). cDNA amplification primers were
designed to encompass the entire coding sequence of the
gene, corresponding to amino acid positions 1-543. Induction
of recombinant protein synthesis and subsequent purification
by Ni 2+-NTA column were performed according to the
manufacturer's instructions (9). A truncated or short protein
(N-terminal half, Q26-R273) was also expressed in E. coli by
using the histidine-tag-containing vector pQE30 (Qiagen).
Generation of mouse hybridomas. BALB/c female mice were
inoculated intra-muscularly with pCIneo-OY-TES-1 plasmid
(30 µg) twice at an interval of 2 weeks, followed 1 month
later by boosting with the truncated N-half OY-TES-1
protein (Q26-R273) (10 µg) intravenously. Spleen cells from
immunized mice fused with mouse myeloma cell line NS-1,
and supernatants from sequentially cloned populations were
screened against the immunizing protein by solid phase ELISA
(19).
Immunohistochemistry (IHC). Tumor specimens were fixed
with buffered-formalin and embedded in paraffin. Sections
(5 µm) were placed on glass slides, heated at 60˚C for 20 min,
and then deparaffinized with xylene and ethanol. For antigen
retrieval, tumor specimens mounted on glass slides were
immersed into preheated antigen retrieval solution (Dako
high pH solution, Capinteria, CA) for 20 min and allowed to
cool for 20 min at room temperature. After the inactivation of
endogenous peroxidase, mAb to OY-TES-1 (clone UA-199)
was then added at a concentration of 2.5 µg/ml and incubated
overnight at 4˚C. The primary antibody was detected with
a biotinylated anti-mouse IgG (Dako, Capinteria, CA).
Diaminobenzidine tetrahydrochloride was then added for
development for 10 min, followed by counterstaining with
hematoxylin solution.
The extent of immunohistochemical reactivity was graded
as follows: negative, focal, staining of single cells or small
INTERNATIONAL JOURNAL OF ONCOLOGY 29: 903-910, 2006
clusters of cells (~<5% cells stained); +, 5-25%; ++, >25-50%;
+++, >50-75%; and ++++, >75% of cells stained. Negative
control slides omitting the primary antibody were included in
all assays.
ELISA. Recombinant OY-TES-1 protein (2 µg/ml) in 0.05 M
carbonate buffer (pH 9.6) was absorbed to 96-well plates
(Nunc, Roskilde, Denmark) at 4˚C overnight. Plates were
washed with PBS/Tween and blocked with 5% FCS/PBS at
room temperature for 1 h. After washing, serum dilutions
(100 µl) in 5% FCS/PBS were added and incubated at room
temperature for 2 h. Plates were washed and incubated with
secondary antibody (goat anti-human IgG-AP; Southern
Biotechnology, Birmingham, AL) at 1/2,000 dilution for 1 h
at room temperature. Plates were washed and incubated with
the substrate solution (1,2-phenylenediamine dihydrochloride)
for 20 min at room temperature. After addition of 3 M H2SO4
(100 µl), the absorbance was determined with a microplate
reader (Tosoh, Tokyo). Sera were tested over a range of 4-fold
dilutions from 1:100 to 1:100,000, as described previously (20).
Statistical analysis. All statistical analyses were performed
with the SPSS software (21). Statistical correlations were
calculated using Pearson's R Product Moment Correlation
Coefficient. The distribution of OY-TES-1 expression and
clinical outcome was analyzed by the ¯2 test. Estimated survival
distributions were calculated by the method of Kaplan and
Meier (22) and tests of significance with respect to survival
distributions were based on the log-rank test (23). No adjustments were made for multiple comparisons.
Results
Study population. The characteristics of the study population are
presented in Table I. The median age of the study population
was 64 years (range 26-89 years) and the median duration
of follow-up was 34 months (range 0.36-131 months). As
expected, the majority of patients presented with grade 3 tumors
(85%), at stage IIIC (69%) and with serous differentiation
(74%). A complete response to therapy was achieved in 57
of the 100 patients (57%); a partial response was achieved
in 40 patients (40%) while the remaining patients had no
response. The median estimated overall survival for all patients
was 50 months (95% CI 36-64 months) while the median
disease-free survival, excluding patients with persistent/
progressive disease after initial therapy, was 37 months (95%
CI 4-69 months).
Expression of OY-TES-1 mRNA in normal tissues, cell lines
and EOC specimens. Expression of OY-TES-1 mRNA in a
panel of normal tissues, immortalized normal ovarian surface
epithelial cell lines (IOSE and HOSE), ovarian cancer cell
lines and epithelial ovarian tumor specimens was investigated
by RT-PCR. Intensities of PCR products in tumor specimens
were found to be heterogeneous, and some specimens yielded
only faint amplicons. These were scored positive only if the
result could be reproduced by a repeated RNA extraction
and specific RT-PCR from the same tumor specimen. Cases
with very low transcript levels, which were not reproducibly
positive, were not regarded as positive. The normal ovarian
905
Table I. Patient characteristics.
–––––––––––––––––––––––––––––––––––––––––––––––––
Characteristics
–––––––––––––––––––––––––––––––––––––––––––––––––
Evaluable patients
100
Age (median/range), years
64 (26-89)
Follow-up (median /range), monthsa
34 (36-131)
Grade, n
1
2
3
6
8
85
FIGO stage, n (%)
1A
1B
1C
IIA
IIB
IIC
IIIA
IIIB
IIIC
IV
4 (4)
1 (1)
3 (3)
1 (1)
1 (1)
5 (5)
1 (1)
2 (2)
74 (74)
8 (8)
Histology, n (%)
Papillary serous
Clear cell
Endometroid
Mucinous
Undifferentiated
Others (transitional, mixed, carcinosarcoma)
74 (74)
7 (7)
5 (5)
2 (2)
3 (3)
9 (9)
Response to frontline therapy, n (%)
Complete response
Partial response
Progression
Unknown
57 (57)
40 (40)
1 (1)
2 (2)
Recurrencesb, n (%)
Recurrence/persistent disease
70 (70)
Current status, n (%)
Alive, NEDc
Alive with disease
Dead of disease
Dead from other causes
32 (32)
17 (17)
51 (51)
0
Antigen status (RT-PCR and/or IHC), n (%)
OY-TES-1 positive (either method)
69 (69)
OY-TES-1 positive (RT-PCR only)
23 (23)
OY-TES-1 positive (IHC only)
60 (63)
–––––––––––––––––––––––––––––––––––––––––––––––––
aMedian
survival for all patients: 50 months (CI 36-64 months).
disease-free survival (excluding patients with persistent
disease): 37 months (4-69 months). cNED, no evidence of disease.
bMedian
–––––––––––––––––––––––––––––––––––––––––––––––––
906
TAMMELA et al: OY-TES-1 EXPRESSION AND IMMUNOGENICITY IN OVARIAN CANCER
Table II. Correlation between OY-TES-1 IHC expression and
and clinico-pathological features in epithelial ovarian cancer.
–––––––––––––––––––––––––––––––––––––––––––––––––
Pathological and clinical features
Positive
Negative
–––––––––––––––––––––––––––––––––––––––––––––––––
40 (40%)
Evaluable patients (n=100)
60 (60%)a
Age (median/range), years
64 (26-89)
64 (29-85)
Grade, n (%)
1
2
3
4
6
50
2
2
31
FIGO stage, n (%)
1A
1B
1C
IIA
IIB
IIC
IIIA
IIIB
IIIC
IV
3
1
1
0
0
3
4
1
43
3
1
0
1
1
1
1
1
0
24
5
43
3
4
1
3
6
26
4
1
1
0
3
Response to frontline therapy,
n (%)
Complete response
Partial response
Progression
Unknown
37 (62)
22 (37)
0
1 (1)
17 (48)
16 (46)
1 (3)
1 (3)
Recurrencesb, n (%)
Recurrence/persistent disease
39 (65)
27 (77)
Histology, n
Papillary serous
Clear cell
Endometroid
Mucinous
Undifferentiated
Others (transitional,
mixed, carcinosarcoma)
Current status, n (%)
Alive, NEDc
21 (35)
10 (29)
Alive with disease
11 (18)
5 (14)
Dead of diseased
28 (47)
20 (57)
–––––––––––––––––––––––––––––––––––––––––––––––––
aFocal,
<5% (37% of patients); +, <25% (17% of patients); ++,
>25-50% (14% of patients); +++, >50-75% (11% of patients);
++++, >75% (14% of patients). bProgression-free survival for
patients with OY-TES-1 mRNA-negative tumor was 39 (CI 8, 69)
months and 37 (CI 1, 72) months for IHC-positive patients (p=0.82).
cNED, no evidence of disease. dMedian survival for patients with
OY-TES-1 mRNA-negative tumors was 44 (CI 28, 59) months and
50 (CI 34, 66) months for IHC-positive patients (p=0.38).
–––––––––––––––––––––––––––––––––––––––––––––––––
Figure 1. RT-PCR analysis for OY-TES-1 mRNA expression. Shown is
mRNA from EOC specimens (lanes 1-6, negative), normal ovary (lane 7,
negative), Testis (lane 8, positive), EOC specimens (lane 9-11, positive),
EOC specimen (lane 12, negative). GAPDH, glyceraldehyde-3-phosphate
dehydrogenase.
Figure 2. SDS-PAGE of recombinant OY-TES-1 protein (N-terminal half).
surface epithelial cell lines, IOSE and HOSE, did not express
OY-TES-1. The normal tissue panel consisting of ovary,
colon, spleen, prostate, and small intestine did not express
OY-TES-1. The thymus and leukocyte were weakly positive.
Also, one of the five ovarian cancer cell lines, SKOV3, was
positive for the antigen while the remaining were negative.
OY-TES-1 mRNA expression was detected in 23/100 (23%)
of tumor specimens (Fig. 1).
Production of recombinant OY-TES-1 protein and mouse
mAbs. The truncated N-terminal half protein was used for the
generation of mouse monoclonal antibodies for immuno-
INTERNATIONAL JOURNAL OF ONCOLOGY 29: 903-910, 2006
907
Figure 3. Immunohistochemical staining of OY-TES-1 antigen with mAb
UA-199. Magnification: a, x20; b-e, x10. a, normal testis indicating
seminiferous tubules with strong intratubular staining of mostly spermatocytes with less staining of early spermatogenic cells. b-e, UA-199 staining
of serous papillary EOC showing +, ++, +++, ++++ immunoreactivity
patterns.
Figure 4. ELISA reactivity of recombinant OY-TES-1 protein (N-terminal half) in patients and healthy controls. Mab UA-199 was used as positive control.
Two patients with liver cancer (liver ca-1 and liver ca-2) and one patient with prostate cancer demonstrated serum immunoreactivity to OY-TES-1. b, ELISA
reactivity of recombinant OY-TES-1 protein in ovarian cancer patients. Patient 15 demonstrated antibody response against OY-TES-1.
histochemistry. Four hybridoma clones, designated UA-11,
UA-60, UA-144 and UA-199, secreting mAbs that showed
reactivity against recombinant OY-TES-1 were harvested
and subcloned. UA-199 exhibited the highest titer against
OY-TES-1 recombinant protein in ELISA and was used for
immunohistochemistry. The purified truncated protein had an
apparent molecular weight of 37 kDa by SDS-PAGE (Fig. 2),
and was used for ELISA.
908
TAMMELA et al: OY-TES-1 EXPRESSION AND IMMUNOGENICITY IN OVARIAN CANCER
had expression of OY-TES-1 that was 3+ positive by IHC.
Fig. 4b illustrates titration curves with sera from selected
ovarian cancer patients.
Figure 5. Kaplan-Meier estimates of overall survival in EOC patients
according to tumor expression of OY-TES-1.
Expression of OY-TES-1 by immunohistochemistry. OY-TES-1
exhibited intense immunostaining of the germ cells of the
testis (Fig. 3a). Our results indicate that seminiferous tubules
had strong intratubular staining of mostly spermatocytes with
less staining of early spermatogenic cells. This is consistent
with the location of the protein in the sperm acrosome of
other species (9). There was no reactivity with Sertoli cell or
interstitial tissue. There was also no reactivity in a panel of
normal tissues consisting of brain, heart, lung, skeletal muscle,
kidney, ovary and stomach.
Positive staining was observed in 60 of 100 (60%) archived,
formalin-fixed, paraffin-embedded ovarian cancer samples.
Reactivity was mostly heterogeneous, i.e., present in discrete
areas of the tumors (focal or ‘+’ staining according to our
grading). Fig. 3b-e is an example of the observed staining
patterns. The predominant expression pattern was heterogenous
(focal, +, ++), occurring in 42/60 (70%) of OY-TES-1-positive
specimens, while the remaining 18/60 (30%) demonstrated
+++ or ++++ staining. Expression of OY-TES-1 by either
RT-PCR and/or IHC was demonstrable in 69/100 (69%)
tumors.
Antibody response to OY-TES-1 in ovarian cancer patients.
The ELISA reactivity of the full-length recombinant protein
and the truncated N-terminal OY-TES-1 protein was assessed.
We observed the same serum reaction against both full-length
and N-terminal polypeptide. A representative serum reactivity
pattern against the N-terminal half of the OY-TES-1 protein
in a panel of healthy controls and patients with liver, prostate
and colon cancers is shown in Fig. 4a. Two patients with
liver cancer, and a patient with prostate cancer demonstrated
an antibody response to OY-TES-1.
A total of 21 pre-operative serum samples were analyzed
by ELISA for OY-TES-1 antibody. Ten of the serum samples
were from patients whose tumors expressed OY-TES-1,
while the rest were from OY-TES-1 negative patients. There
was a demonstrable antibody response to OY-TES-1 in 1/10
(10%) patients with OY-TES-1 expressing tumors. All of the
patients without OY-TES-1 expressing tumors were also
negative by ELISA. The patient that had an antibody response
Correlation of OY-TES-1 expression with clinical outcome.
Patients whose tumors expressed OY-TES-1 by RT-PCR
and/or IHC had a median disease-free survival of 22 months
(95% CI 13-30 months) compared with 39 months (95% CI
2-75 months) among patients whose tumors did not express
OY-TES-1 (p=0.43). Patients whose tumors expressed OYTES-1 had a trend towards worse median overall survival of
43 months (95% CI 31-55 months) compared to 50 months
(95% CI 32-68) among patients whose tumors did not express
OY-TES-1 (p=0.20) (Fig. 5). When all patients with tissue
expression of OY-TES-1 were considered, no significant
correlation was observed with stage, grade, histology, diseasefree or overall survival. The single patient with evidence of
specific humoral immune response to OY-TES-1 initially had
optimal surgical debulking of stage IIIC papillary serous of
the ovary, and is alive without evidence of disease, 40 months
after initial adjuvant carboplatin and paclitaxel chemotherapy.
Discussion
One of the major barriers to antigen-specific immunotherapy
in epithelial ovarian cancer (EOC) is the lack of well-defined
immunogenic tumor antigens. The need to identify and
characterize tumor antigens in EOC has become even more
compelling because of recent evidence demonstrating that the
presence of intratumoral T cells correlates with improved
clinical outcome (24,25), suggesting that efforts to stimulate
and/or augment the anti-tumor immune response are likely
to be of particular benefit in this disease. In order to assess
the utility of OY-TES-1, a new member of the CT family of
antigens as a target for specific immunotherapy of EOC, we
utilized conventional RT-PCR for mRNA expression and
generated antibody for protein expression. Our results indicate
aberrant expression of OY-TES-1 mRNA and protein in 23 of
100 (23%) and 60/100 (60%) of EOC specimens respectively.
The frequency of OY-TES-1 expression in ovarian cancer
observed in our study is higher than the reported frequency of
expression of other CT antigens in ovarian cancer (13-15,26).
In a separate recent study of OY-TES-1 expression in other
cancer tissues, we detected OY-TES-1 mRNA in 3/20 breast
cancers, 2/5 liver cancers, 1/20 lung cancers, 2/38 colon
cancers, 0/5 stomach cancers, 0/10 renal cancers, 4/18
ovarian cancers, and 5/20 endometrial cancers in the Japanese
population (Nakayama E, personal communication).
In our study, we observed a discrepancy in the frequency
of expression of OY-TES-1 at the mRNA and protein levels.
Since the antibody used in our study (UA-199) stained normal
human testes (positive control) appropriately, and did not
stain a panel of other normal tissues, the relatively high
frequency of expression by IHC is unlikely to be due to
issues of antibody specificity. Additionally, only 13 of the 60
tumors that were classified as positive by IHC had a focal
staining pattern. While it is possible that the relatively large
amplicon size of the OY-TES-1 mRNA was not detectable
in our RT-PCR analysis of some of the tumor tissues, our
results may also reflect tumor heterogeneity with regards
INTERNATIONAL JOURNAL OF ONCOLOGY 29: 903-910, 2006
to antigen expression. Alternatively, IHC may be identifying
an alternatively spliced protein or a truncated protein that
the primers used in RT-PCR are not able to detect. These
findings suggest that both RT-PCR and IHC analysis are
important in the assessment of OY-TES-1 expression in tumor
tissues.
In an effort to determine the inherent immunogenicity of
OY-TES-1 in patients with EOC, we studied a subset of 21
patients where tumor and serum specimens from the same
patients were available. Of these twenty-one patients, ten
had OY-TES-1-positive tumors. The results showed that
OY-TES-1 antibody was found in 10% (1/10) of patients with
OY-TES-1-positive tumors. In a survey of sera from 70 normal
individuals and 234 cancer patients for antibodies against a
panel of CT antigens, Stockert et al (20) reported NY-ESO-1
antibodies in 19 patients (four with EOC), MAGE-1 antibodies
in three patients (one with melanoma, one with EOC, and
one with lung cancer), MAGE-3 antibody in two patients
(both with melanoma), and SSX2 antibody in one patient with
melanoma. No antibody against any of the CT antigens was
found in healthy individuals. Although we have not tested
antigen-specific CD8+ T cell responses to OY-TES-1 in the
current study, parallel results for NY-ESO-1 indicate that a
humoral immune response to NY-ESO-1 was predictive of a
strong CD8+ T cell response (27). Clearly, the analysis of
OY-TES-1-specific cytotoxic T cells in EOC is warranted
to shed additional light on the nature of the spontaneous
immune response to this antigen.
OY-TES-1 is a proacrosin binding protein sp32 precursor
thought to be involved in packaging acrosin in the acrosome
in the sperm head and the antigen of interest in this study.
While OY-TES-1 has a known role in gametogenesis, its role
in cancer, along with the majority of the other CT antigens, is
unknown. Although the lack of correlation between OY-TES-1
expression and clinico-pathologic characteristics (histologic
type, tumor grade, recurrence and survival) may reflect the
fact that the majority of the patients (Table I) had advancedstage disease, it may also imply that the antigen is not critical
for tumor progression. Interestingly, Scanlan et al (12)
have shown that 11/13 non-gametogenic tissues examined
showed moderate to high levels (0.1-2.0 mcg cDNA product
detected) of OY-TES-1 expression by RT-PCR compared to
high levels (>2.0 mcg cDNA product tested) in the testis.
In addition, Kubuschok et al (28) recently demonstrated
expression of OY-TES-1 by RT-PCR in 11/12 normal tissues
(adrenal gland, bladder, brain, endometrium, liver, lymph
node, ovary, small intestine, stomach, thyroid and tonsil);
and in 5/6 non-malignant pancreatic tissues (2 specimens of
normal pancreas and 4 of chronic pancreatitis). While these
findings call into question the classification of OY-TES-1 as a
CT antigen, the tissue restricted distribution and inherent
immunogenicity support the notion that OY-TES-1 could be
a valuable vaccine target in EOC. Indeed, the only patient
with antibody response to OY-TES-1 has demonstrated an
unusually favorable course with no evidence of disease after
40 months of follow-up. This finding underscores the need
for additional analysis to define the role of spontaneous or
vaccine-induced OY-TES-1 immunity on the course of EOC.
In conclusion, although the tissue restricted expression of
OY-TES-1 is not as tight as other CT antigens, it could still
909
represent a potential target for active specific immunotherapy in
EOC because of aberrant expression in a high proportion of
EOC patients and inherent immunogenicity. The role of OYTES-1 in tumor progression, if any, remains to be elucidated.
Also, the fact that OY-TES-1, like many tumor antigens, is
expressed only in a subset of patients with EOC underlines the
need for identifying other antigens that could serve as targets
for immunotherapy. To that end, we have continued with
extensive analysis of CT antigens in EOC to uncover additional
antigenic targets for polyvalent vaccine development.
Acknowledgements
This study was supported by the Cancer Research Institute/
Ludwig Institute for Cancer Research Cancer Vaccine
Collaborative Grant. Dr Kunle Odunsi is supported by the
Cancer Research Institute's Anna-Marie Kellen Clinical
Investigator Award.
References
1. Greenlee RT, Hill-Harmon MB, Murray T and Thun M: Cancer
statistics, 2001. CA Cancer J Clin 51: 15-36, 2001.
2. Engel J, Eckel R, Schubert-Fritschle G, et al: Moderate progress
for ovarian cancer in the last 20 years: prolongation of survival,
but no improvement in the cure rate. Eur J Cancer 38: 2435-2445,
2002.
3. Brichard V, Van Pel A, Wolfel T, et al: The tyrosinase gene codes
for an antigen recognized by autologous cytolytic T lymphocytes
on HLA-A2 melanomas. J Exp Med 178: 489-495, 1993.
4. Scanlan MJ, Chen YT, Williamson B, et al: Characterization
of human colon cancer antigens recognized by autologous
antibodies. Int J Cancer 76: 652-658, 1998.
5. Cheever MA, Disis ML, Bernhard H, et al: Immunity to
oncogenic proteins. Immunol Rev 145: 33-59, 1995.
6. Tindle RW: Human papillomavirus vaccines for cervical cancer.
Curr Opin Immunol 8: 643-650, 1996.
7. Boon T and van der Bruggen P: Human tumor antigens recognized
by T lymphocytes. J Exp Med 183: 725-729, 1996.
8. Chen YT, Scanlan MJ, Sahin U, et al: A testicular antigen
aberrantly expressed in human cancers detected by autologous
antibody screening. Proc Natl Acad Sci USA 94: 1914-1918, 1997.
9. Ono T, Kurashige T, Harada N, et al: Identification of proacrosin
binding protein sp32 precursor as a human cancer/testis antigen.
Proc Natl Acad Sci USA 98: 3282-3287, 2001.
10. Zendman AJ, Ruiter DJ and van Muijen GN: Cancer/testisassociated genes: identification, expression profile, and putative
function. J Cell Physiol 194: 272-288, 2003.
11. Kirkin AF, Dzhandzhugazyan KN and Zeuthen J: Cancer/testis
antigens: structural and immunobiological properties. Cancer
Invest 20: 222-236, 2002.
12. Scanlan MJ, Simpson AJ and Old LJ: The cancer/testis genes:
review, standardization, and commentary. Cancer Immun 4: 1,
2004.
13. Odunsi K, Jungbluth AA, Stockert E, et al: NY-ESO-1 and
LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 63: 6076-6083,
2003.
14. Yamada A, Kataoka A, Shichijo S, et al: Expression of MAGE1, MAGE-2, MAGE-3/-6 and MAGE-4a/-4b genes in ovarian
tumors. Int J Cancer 64: 388-393, 1995.
15. Yakirevich E, Sabo E, Lavie O, Mazareb S, Spagnoli GC and
Resnick MB: Expression of the MAGE-A4 and NY-ESO-1
cancer-testis antigens in serous ovarian neoplasms. Clin Cancer
Res 9: 6453-6460, 2003.
16. Tammela J, Jungbluth AA, Qian F, et al: SCP-1 cancer/testis
antigen is a prognostic indicator and a candidate target for
immunotherapy in epithelial ovarian cancer. Cancer Immun 4:
10, 2004.
17. Baba T, Azuma S, Kashiwabara S and Toyoda Y: Sperm from
mice carrying a targeted mutation of the acrosin gene can
penetrate the oocyte zona pellucida and effect fertilization. J
Biol Chem 269: 31845-31849, 1994.
910
TAMMELA et al: OY-TES-1 EXPRESSION AND IMMUNOGENICITY IN OVARIAN CANCER
18. Serov SF, Scully RE and Sobin LH: Histological typing of ovarian
tumors. International Classification of Tumors. World Health
Organization, 1973.
19. Dippold WG, Lloyd KO, Li LT, Ikeda H, Oettgen HF and
Old LJ: Cell surface antigens of human malignant melanoma:
definition of six antigenic systems with mouse monoclonal
antibodies. Proc Natl Acad Sci USA 77: 6114-6118, 1980.
20. Stockert E, Jager E, Chen YT, et al: A survey of the humoral
immune response of cancer patients to a panel of human tumor
antigens. J Exp Med 187: 1349-1354, 1998.
21. Kaplan EL and Meier P: Non-parametric estimation from
incomplete observations. J Am Statist Assoc 53: 457-486,
1958.
22. Cox DR: Regression models and life-tables. J Royal Stat Soc
34: 187-220, 1972.
23. Burnet M: Cancer: a biological approach. III. Viruses associated
with neoplastic conditions. IV. Practical applications. Br Med J:
841-847, 1957.
24. Zhang L, Conejo-Garcia JR, Katsaros D, et al: Intratumoral T
cells, recurrence, and survival in epithelial ovarian cancer. N
Engl J Med 348: 203-213, 2003.
25. Sato E, Olson SH, Ahn J, et al: Intraepithelial CD8+ tumor
infiltrating lymphocytes and high CD8+/Treg ratio are associated
with favorable prognosis in epithelial ovarian cancer. Proc Natl
Acad Sci USA 102: 1538-1543, 2005.
26. Tammela J, Jungbluth AA, Qian F, et al: SCP-1 ‘cancer/testis’
antigen is a prognostic indicator and a candidate target for
immunotherapy in epithelial ovarian cancer. Cancer Immun (In
Press).
27. Jager E, Nagata Y, Gnjatic S, et al: Monitoring CD8 T cell
responses to NY-ESO-1: correlation of humoral and cellular
immune responses. Proc Natl Acad Sci USA 97: 4760-4765, 2000.
28. Kubuschok B, Xie X, Jesnowski R, et al: Expression of cancer
testis antigens in pancreatic carcinoma cell lines, pancreatic
adenocarcinoma and chronic pancreatitis. Int J Cancer 109:
568-575, 2004.